Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IGFBPL1 (A*02) T Cell Engager
- Development stage
- Preclinical
- Lead developer
- MyriO Tx
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IGFBPL1 (A*02) T Cell Engager is a bispecific antibody being developed by Myrio Therapeutics for the treatment of small cell lung cancer (SCLC). The therapeutic is designed to target a specific peptide derived from Insulin-like growth factor-binding protein-like 1 (IGFBPL1) that is presented on the cell surface by the HLA-A*02 major histocompatibility complex (MHC). As a T-cell engager, the molecule simultaneously binds to this tumor-specific peptide-HLA complex and the CD3 receptor on T cells, thereby recruiting and activating cytotoxic T cells to selectively destroy IGFBPL1-positive tumor cells. The program is currently in the discovery phase of development.
- Other names
- IGFBPL1 A*02 T-cell engager
02
Targets
CD3 (T-cell surface glycoprotein CD3)IGFBPL1/HLA-A*02:01 (Insulin-like growth factor-binding protein-like 1-derived peptide presented by HLA-A*02:01)MHC I (MHC class I})IGFBPL1 (Insulin-like growth factor-binding protein-like 1)
Beyond the preview
Go deeper on IGFBPL1 (A*02) T Cell Engager.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IGFBPL1 (A*02) T Cell Engager.